Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy

Figure 1 Stages of chronic antibody-mediated chronic rejection. PTC: Peritubular capillaries.

Figure 2 Proposed pathogenetic mechanisms for transplant glomerulopathy.

Figure 3 Five year post-transplant graft survival according 1-year post-transplant surveillance biopsy.

Figure 4 Deterioration of kidney allograft function study. Graft survival at 2-year according presence of donor-specific-HLA antibodies (DSAs) and/or C4d. HLA: Human leukocyte antigens.

Figure 5 Actual 5-year post-transplantation cumulative incidence of de novo donor-specific-human leukocyte antigens antibodies (DSA). DSA:Donor-specific-human leukocyte antigens antibodies.

Figure 6 Probability of graft loss within 3 years after de novo donor-specific-human leukocyte antigens antibodies appearance. DSA:Donor-specific-human leukocyte antigens antibodies.